Business · 06/07/2022Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for VYEPTI Patent Extension
Summary
The US Food and Drug Administration has officially approved the regulatory review period for VYEPTI, a human biological product, following a submission to the US Patent and Trademark Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →